All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Jean-Jacques Kiladjian, Université de Paris and Hôpital Saint-Louis, Paris, FR. We asked, Which factors may predict long-term outcomes with ropeginterferon alfa-2b for the treatment of polycythemia vera (PV)?
Which factors may predict long-term outcomes with ropeginterferon alfa-2b for the treatment of PV?
Kiladjian discusses factors that are independently associated with a positive outcome with ropeginterferon alfa-2b therapy. In a cohort of patients from Hôpital Saint-Louis, two factors associated with such a potential operational cure were found: patients who received at least 2 years of ropeginterferon alfa-2b therapy with complete response, and the mutant allele burden of the JAK2 mutation.
What is the news about ropeginterferon?
During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee Chair, Jean-Jacques Kiladjian, Université de Paris, Paris, FR, about ropeginterferon alfa-2b.
PROUD-PV/CONTINUATION-PV studies: benefits of ropeg IFN alfa-2b for the treatment of PV
The MPN Hub were pleased to speak to Jean-Jacques Kiladjian, University of Paris, Paris, FR, during the 61st American Society of Hematology (ASH) meeting in...
Subscribe to get the best content related to MPN delivered to your inbox